Credit Suisse’s Profound Medical PROF Stock Holding History

Credit Suisse’s Portfolio PROF Stock Details PROF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-400	Closed	-$3K	–	4225
2022 Q2	$3K	Buy	+400	New	+$3.16K	﹤0.01%	3776

Other funds holding PROF

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

LBA

Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return

TIM

Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

ZDA

Zweig-DiMenna Associates New York $722M AUM 97.69% 1-Year Est. Return

Credit Suisse's PROF Position: Q3 2022 in Review

Credit Suisse sold out of Profound Medical (PROF) in Q3 2022, closing a stake of 400 shares — an estimated $3K sold.

Credit Suisse first reported a position in PROF in Q2 2022 and held it in 1 quarter. The position peaked at $3K in Q2 2022. 35 funds tracked by Wall St. Rank hold PROF as of Q3 2022.

Credit Suisse reported no remaining Profound Medical position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 400 Profound Medical shares in Q3 2022, an estimated $3K.
Credit Suisse first reported a position in Profound Medical in Q2 2022 and held it in 1 quarter.
Credit Suisse's Profound Medical position peaked at $3K in Q2 2022.
35 funds tracked by Wall St. Rank held Profound Medical as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.